TFG Advisers LLC Trims Stake in Johnson & Johnson $JNJ

TFG Advisers LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 11,212 shares of the company’s stock after selling 372 shares during the period. TFG Advisers LLC’s holdings in Johnson & Johnson were worth $1,713,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Elios Financial Group Inc. grew its stake in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after acquiring an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its holdings in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after purchasing an additional 67 shares during the period. MBA Advisors LLC boosted its holdings in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after purchasing an additional 68 shares during the period. Sovereign Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its holdings in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after purchasing an additional 69 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on JNJ shares. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America increased their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Finally, Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $187.47.

Johnson & Johnson Stock Up 1.4%

NYSE:JNJ opened at $188.51 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.78. The stock has a market capitalization of $453.98 billion, a P/E ratio of 20.16, a P/E/G ratio of 2.37 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company’s 50-day simple moving average is $176.18 and its 200-day simple moving average is $162.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the business earned $2.82 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.